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Abstract: Monoclonal antibodies (MAbs) have been employed either for diagnosis or 
treatment of infections caused by different pathogens. Specifically for Shiga  
toxin-producing Escherichia coli (STEC), numerous immunoassays have been developed 
for STEC diagnosis, showing variability in sensitivity and specificity when evaluated by 
reference laboratories, and no therapy or vaccines are currently approved. Thus, the aim of 
this work was the characterization of the interaction between MAbs against Stx1 and Stx2 
toxins and their neutralizing abilities to enable their use as tools for diagnosis and therapy. 
The selected clones designated 3E2 (anti-Stx1) and 2E11 (anti-Stx2) were classified as 
IgG1. 3E2 recognized the B subunit of Stx1 with an affinity constant of 2.5 × 10−10 M, 
detected as little as 6.2 ng of Stx1 and was stable up to 50 ºC. In contrast, 2E11 recognized 
the A subunit of Stx2, was stable up to 70 ºC, had a high dissociation constant of   
6.1 × 10−10 M, and detected as little as 12.5 ng of Stx2. Neutralization tests showed that 
160 ng of 3E2 MAb inhibited 80% of Stx1 activity and 500 µg 2E11 MAb were required 
for 60% inhibition of Stx2 activity. These MAb amounts reversed 25 to 80% of the 
cytotoxicity triggered by different STEC isolates. In conclusion, these MAbs show suitable 
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characteristics for their use in STEC diagnosis and encourage future studies to investigate 
their protective efficacy. 
Keywords: Stx1; Stx2; monoclonal antibodies; binding; stability; detection; neutralizing 
ability; specificity 
 
1. Introduction 
Shiga toxin-producing Escherichia coli (STEC) strains and their subset, the enterohemorrhagic  
E. coli (EHEC) strains, contain a large pathogenicity island called the locus of enterocyte effacement 
and carry a 90-kb plasmid [1–3]. Not only the O157:H7 serotype, but also some other STEC serotypes 
have been associated mainly with food-linked outbreaks of Stx-mediated disease with the possibility of 
a complication such as the hemolytic uremic syndrome (HUS), which is characterized by hemolytic 
anemia, thrombocytopenia, and renal failure. 
Shiga toxins (Stxs) are known to act systemically and therefore must cross from the site of STEC 
colonization in the gastrointestinal tract to the circulatory system [3]. There are two main subtypes of 
Stxs, Stx/Stx1 and Stx2. Stx and Stx1 are practically identical, with only one amino acid difference in 
the A subunit. The A and B subunits of Stx1 and Stx2 differ at the amino acid level by 32 and 27%, 
respectively, although their crystal structures show high similarity [4,5]. 
Stxs have the AB5 structure, where the active domain (A–32 kDa) contains an N-glycosidase. This 
enzyme depurinates the 28S rRNA of the 60S ribosomal subunit and irreversibly inhibits protein 
synthesis, resulting in cell death. Subunit B consists of five identical 7.7-kDa monomers that form a 
pentamer, which allows the C terminus domain of the A2 peptide to traverse it. The B pentamer binds 
to the eukaryotic receptor globotriaosylceramide (Gb3Cer/CD77) or globotetraosylceramide (Gb4Cer) 
in the case of Stx2e [6–10], present on the plasma membrane of enterocytes and other cells, for 
example glomerular endothelial cells [10]. 
The Vero cell toxicity test detects functionally active toxin and is often used as the gold standard to 
evaluate diagnostic immunoassays [11,12]. Among the several commercially available immunoassays 
using monoclonal and/or polyclonal antibodies are VTEC-Screen (Seiken, Japan), Premier EHEC 
(Meridian Bioscience, US), Ridascreen Verotoxin (R-Biopharm, Germany), ProSpecT Shiga Toxin 
(Alexon-Trend, US), Immunocard STAT! EHEC (Meridian Diagnostics, US) and Duopath Verotoxins 
Gold Labeled Immunosorbent Assay (Merck, Germany). Some of them differentiate between Stx1 and 
Stx2 while others do not. The reported sensitivities and specificities of these immunoassays vary by 
test format and manufacturer. The standard by which each manufacturer evaluates its tests also varies; 
therefore, a direct comparison of performance characteristics of various immunoassays has not been 
performed [13]. 
Outbreaks of STEC infections can be contained by sanitary measures and by monitoring the water 
and food supply. Hence, immunization of the general population cannot be justified given the safety 
restrictions of a vaccine. Treatment of infected patients is needed to prevent progression of the 
infection to HUS [14]. However, despite remarkable advances in understanding STEC pathogenesis, 
the clinical options for treatment remain limited to mainly supportive strategies. The use of 
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antimicrobials is controversial; mainly reflected by the effect of specific antimicrobial agents on phage 
induction and subsequent Stx gene expression and transcription [15], thereby allowing the undesirable 
release of verotoxin Stx, and thus being usually avoided [16–18]. 
There is no current approved treatment to combat or prevent illness from STEC, but several 
promising options for the future are under investigation. These options include several vaccine 
candidates such as Stx1 and Stx2 genetic toxoids, a plant-based Stx2 toxoid and a chimeric 
StxA2/StxB1 toxoid that elicits a neutralizing antibody response and provides protection against a 
lethal challenge of both Stx1 and Stx2 [19–21]. Passive immunization with monoclonal antibodies rose 
against Stx1 and Stx2 has been shown to be effective in animal models [22–30], and urtoxazumab, a 
humanized monoclonal antibody against Shiga-like toxin 2 is undergoing clinical trials [31]. 
Therefore, these compelling, important aspects of STEC infection relative to diagnosis and therapy 
motivated us to produce monoclonal antibodies against Stx1 and Stx2. In the present study, we 
demonstrated their interactions and neutralization of Shiga toxins, and the results obtained support 
their use as tools in STEC diagnosis and encourage future studies to investigate their  
protective efficacy. 
2. Material and Methods 
2.1. Toxins, Chemicals, Reagents, Antibodies and Supplies 
Purified Stx1 and Stx2 were purchased from Tufts University School of Medicine, Boston, MA, 
USA. A Protein A affinity chromatography column was bought from GE Healthcare. Bovine serum 
albumin (BSA), polyethylene glycol 1500, goat anti-mouse IgG peroxidase-conjugated antibodies, 
goat anti-mouse IgG-FITC conjugated, ο-phenylenediamine (OPD) and 3’3’-diaminobenzidine (DAB) 
were acquired from Sigma Aldrich (St Louis, MO, USA). Horseradish peroxidase-conjugated rabbit 
anti-mouse-IgG+A+M purchased from Zymed (San Francisco, CA, USA). HAT—(10 mM 
hypoxanthine, 40 μM aminopterin and 1.6 mM thymidine) and fetal bovine serum (FBS) were 
acquired from GibcoBRL (Itapevi, SP, Brazil). Nitrocellulose membrane Hybond C-Extra was 
acquired from Amersham Biosciences (Little Chalfont, UK). For ELISA assays, we employed 
MaxiSorp microplates from Nunc (Rochester, NY, USA) and assay measurements were done in a 
Multiskan EX ELISA reader from Labsystems (Milford, MA, USA). 
2.2. Bacterial Isolates 
In this study, 45 STEC isolates from human and animal sources, belonging to different serotypes 
previously characterized by the presence of stx gene by polymerase chain reaction (PCR) [32–34] were 
used for MAbs characterization against Stx1 and Stx2. EDL933 was included in the assays as a 
positive control of the strain producing Stx1/Stx2. All strains were cultivated as described by Rocha 
and Piazza [33] to enhance expression of Stx by bacterial isolates and for Vero cell cytotoxicity assay 
(VCA)/neutralization assay.  
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2.3. Stx1 and Stx2 Toxins and Toxoids 
Toxins were converted to toxoids by either formaldehyde or glutaraldehyde treatment using the 
protocol described by Donohue-Rolfe et al. [35] and Brown et al. [36], respectively, before 
immunization of the mice.  
2.4. Anti-Stx1 and Anti-Stx2 Monoclonal Antibody (MAb) Production 
Four to six week-old female BALB/c mice were immunized via the footpad with 10 µg Stx1 or  
3 µg Stx2 toxoid adsorbed to 250 µg aluminum hydroxide. The immunization protocols consisted of 
three booster injections of the toxoid (10 µg) in 0.01 M phosphate buffered saline, pH 7.4 (PBS) at 
four-week intervals for Stx1 toxoid, and two booster injections (15 µg) with a 15-day interval for Stx2 
toxoid. The experiments were conducted in agreement with the Ethical Principles in Animal Research, 
adopted by the Brazilian College of Animal Experimentation, and they were approved by the Ethical 
Committee for Animal Research of Butantan Institute (469/08). 
The mouse with the highest antibody titer was boosted with 10 µg Stx1 or 15 µg Stx2 toxoid three 
days prior to cell fusion. Serum samples were obtained just before the first immunization by the  
retro-orbital sinus method to be used as the negative control in specific antibody evaluation. Serum 
samples were also obtained ten days after the last antigen injection and subsequently analyzed  
by ELISA. 
The popliteal lymphnode cells were fused with SP2/O-Ag14 mouse myeloma cells (2:1) using 
polyethylene glycol 1500 [37], with modifications. Hybrids were selected in RPMI 1640 medium plus 
3% HAT containing 10% FBS at 37 °C and 5% CO2. The supernatant fluids were screened for  
species-specific antibodies by indirect ELISA.  
For ELISA, hybridoma supernatant (100 µL) was added to wells of a 96-well plate previously 
coated with 0.1 µg-purified toxins to screen cultures for antibody production. Antibody-secreting cells 
were expanded and cloned twice at limiting dilution. Hybridomas secreting MAbs were selected using 
STEC and other non-producing Stx isolates by capture ELISA. 
2.5. MAb Characterization 
2.5.1. MAb Isotyping and Purification 
The microplate was coated overnight at 4 °C with 1 µg goat anti-mouse IgG1, IgG2a, IgG2b, IgG3, 
IgA, IgM and IgE in 0.05 M sodium carbonate-bicarbonate buffer (pH 9.6). Hybridoma supernatants 
were incubated with each of the isotype followed by incubation with horseradish  
peroxidase-conjugated rabbit anti-mouse-IgG+A+M (1:1,000). The supernatants from selected clones 
were filtered (0.45 µm) and purified by protein A affinity chromatography. MAb purity was 
determined by 15% polyacrylamide gel electrophoresis containing sodium dodecyl sulfate  
(SDS-PAGE) [38,39] staining with Coomassie blue R-250.  
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2.5.2. Interaction of MAbs with Toxin: Definition of Detection Limit, Affinity and Stability 
Anti-Stx1 and Stx2 MAbs features were determined by ELISA. The detection limit was established 
using toxin concentrations from 100 to 0.09 ng coated on microplates in a PBS solution at 4 °C for  
16–18 h. After blocking (1% BSA at 37 °C for 30 min), toxins were incubated with 0.2 µg anti-Stx1 or 
anti-Stx2 monoclonal antibody diluted in blocking buffer at 37 °C for 1 h, followed by incubation with 
goat anti-mouse peroxidase-conjugated antibody diluted 1:5,000, at 37 °C for 1 h. The reaction was 
developed with 0.5 mg/mL OPD plus hydrogen peroxide (H2O2), and stopped by the addition  
of 1 N HCl. The absorbance was measured at 492 nm in a Multiskan EX ELISA reader. 
The cross reactivity between MAbs and toxins was determined by indirect ELISA using different 
anti-Stx1 or anti-Stx2 MAb concentrations (ranged from 1.0 pg to 10 μg) with a predetermined toxin 
concentration (0.1 μg) as antigen. 
Three-step ELISA described by Friguet et al. [40] was employed to determine the dissociation 
constants (KD) of antigen-antibody interactions under equilibrium conditions. Briefly, dilutions of 
different MAbs, selected in the linear part of the ELISA titration curves (determined by linear 
regression) were incubated overnight at 4 °C with various concentrations of antigen. The concentration 
of free MAb was determined by ELISA, where aliquots (100 μL) of incubation medium were 
transferred to the wells of microtiter plates previously coated with Stx1 or Stx2. Dissociation constants 
were deduced from Scatchard plots. 
The stability of anti-Stx1 and Stx2 MAbs was determined by indirect ELISA in which MAb 
solutions were kept at room temperature, or at 37 °C, 50 °C, 60 °C, 80 °C, 90 °C and 100 °C for  
10 min. Tests were performed at different times up to 2 h. 
2.5.3. Stx1 and Stx2 Characterization by Immunoblotting 
The reactivity of antibodies to purified Stx1 and Stx2 toxins was tested by immunoblotting using 
the monoclonal antibodies. Briefly, 10 μg per slot of toxins were submitted to 15% SDS-PAGE. After 
electrophoresis, the separated proteins were transferred to a nitrocellulose membrane at 150 mA for  
18 h at 4 °C. The membrane was blocked with 1% BSA for 2 h and incubated with anti-Stx1 or  
anti-Stx2 monoclonal antibodies (50 µg) at room temperature for 2 h and at 4 °C for 18 h. Next, the 
membrane was washed and incubated at room temperature for 1 h with peroxidase-conjugated goat 
anti-mouse IgG (1:5,000). After washing, DAB plus H2O2 were added and the reaction was stopped 
after 15 min by the addition of distilled water. 
2.5.4. MAb Reactivity to Shiga Toxin-Producing E. coli 
MAb reactivity to the toxins expressed by STEC isolates was determined by capture ELISA using 
microplates coated with IgG-enriched fraction of anti-Stx1 (1 µg) or anti-Stx2 (3 µg) from rabbit 
polyclonal serum [35,36] at 4 °C for 16–18 h. After blocking with 1% BSA at 37 °C for 30 min,  
100 µL of isolates supernatants were incubated at 37 °C for 2 h followed by incubation with either  
0.5 µg MAb anti-Stx1 or 0.5 µg MAb anti-Stx2. Antigen-antibody binding was detected by the 
addition of goat anti-mouse IgG-peroxidase conjugate (1:5,000) and OPD (0.5 mg/mL) and H2O2 as 
enzyme substrates, and the peroxidase reaction was stopped by the addition of 1 N HCl. The 
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absorbance was measured at 492 nm in a Multiskan EX ELISA reader. MAb reactivity to Stx 
expressed by STEC isolates was arbitrarily defined as low (1–30 ng), medium (31–60 ng) and high 
(61–100 ng) compared to the absorbance obtained with the reactivity of 100 ng of purified toxins, 
which we considered a high reactivity level. 
2.6. Vero Cell Toxin Assays 
Vero cells (1 × 105 cells/mL) were grown in 96-well plates in Dulbecco’s medium (DMEM) in the 
presence of 10% FBS for 24 h for Vero cell assay (VCA) and neutralization assays. Cells were also 
cultivated under the same conditions in 24-well plates containing 13 cm diameter coverslips for 
immunofluorescence assay. 
2.6.1. VCA 
Half-maximal cytotoxic doses (CD50) of the toxins were determined by VCA. Log10 dilutions from 
0.001 pg to 10 µg of each toxin were incubated with Vero cells at 37 °C, in a 5% CO2 atmosphere for 
72 h. This activity was determined as described by Gentry and Dalrymple [41]. Cell viability was 
determined using a spectrophotometer after staining the cells with crystal violet, and the percentage of 
cytotoxicity was calculated using the formula: control A595 nm minus sample A595 nm, divided by 
control A595 nm. Cell monolayer in presence of medium and without toxins was employed as control 
of cell viability. These assays were performed twice in duplicate. 
2.6.2. Monoclonal Antibody Neutralizing Assays 
Neutralizing ability of anti-Stx1 or anti-Stx2 monoclonal antibodies was determined by incubating 
each toxin at the CD50 with different MAb concentrations from 0.4 pg to 100 µg for anti-Stx1 or 0.4 pg 
to 500 µg for anti-Stx2. Culture supernatants of STEC producing Stx1 and/or Stx2 were incubated at 
1:10 dilution with 30 μg anti-Stx1 and 500 μg anti-Stx2 monoclonal antibodies at 37 °C for 2 h.  
Stx1- and Stx2-specific rabbit antisera were employed as neutralizing activity controls [33,34]. After 
incubation, these mixtures were tested as described by Beutin et al. [42]. These assays were performed 
three times in duplicate. 
2.6.3. Immunofluorescence and Confocal Analysis 
The immunofluorescence assay was performed as described by Dorsey et al. [43]. Toxins and cells 
were incubated at 37 °C for 0, 2, 6 and 24 h using 0.1 pg Stx1 or 640 pg Stx2. After this period, cells 
were washed with DMEM containing 2% FBS and then fixed with 4% ρ-formaldehyde for 16–18 h at 
4 °C. The cells were washed three times with PBS and 1% glycine in PBS was added to quench excess 
aldehyde groups. After blocking with PBS containing 1% BSA and incubation with 100 µg anti-Stx1 
or 200 µg anti-Stx2 diluted in blocking buffer at 37 °C for 1 h, the antigen-antibody reaction was 
detected by the addition of anti-mouse IgG-FITC (1:100). The reaction was visualized with a confocal 
laser-scanning microscope (LSM 510 META). The image was obtained and analyzed with a confocal 
microscope Zeiss LSM image browser, and the cut-off was defined as the control reaction of Vero 
cells with either MAb anti-Stx1 or anti-Stx2 plus anti-mouse IgG-FITC in the absence of toxin.  
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2.6.4. Statistical Analysis 
The differences between isolates with regard to cytotoxicity and their corresponding neutralization 
by the MAbs was analyzed by GraphPrism® 5.01, using Student’s t-test and two-away ANOVA. The 
differences were considered statistically significant when p ≤ 0.05. 
3. Results 
3.1. Interaction of Monoclonal Antibodies with Stx1 and Stx2 
The detoxification process was employed to reduce Stx1 and Stx2 toxicity to less than 1% for 
mouse immunization. The immunization protocols used for Stx1 or Stx2 in BALB/c mice generated 
high IgG antibody titers for both toxins. The mean optical density at 492 nm was 1.0 up to 3200-fold 
serum dilution in mice immunized with the two toxins. 
Secretory hybridomas of antibodies against Stx1 and Stx2 were obtained and subcloned by limiting 
dilution. Anti-Stx1 and anti-Stx2 MAbs produced by the selected clones (3E2 and 2E11, respectively), 
were classified as IgG1 and showed reactivity with their respective toxins by immunoblotting:  
anti-Stx1 MAb bound to the B subunit (Figure 1A) with a dissociation constant of 2.5 × 10−10 M 
(Table 1), while anti-Stx2 MAb bound to the A subunit (Figure 1B) with a dissociation constant  
of 6.1 × 10−10 M (Table 1). 
Figure 1. Nitrocellulose membranes containing purified toxins Shiga toxins (Stx)1 and 
Stx2. Immunoblotting reaction was carried out using anti-Stx1 MAb (A) and anti-Stx2 
MAb (B). Apparent molecular weights found showed that the MAbs recognized their 
corresponding toxin. Arrows indicate toxin subunits. 
  
Using 200 ng MAbs to determine their ability to bind to the respective toxin, the detection limit was 
6.2 ng for anti-Stx1 and 12.5 ng for anti-Stx2, using an optical density of 0.1 as cut-off (Table 1). The 
equivalent cut-off was used for determining the reactivity and cross reactivity of MAbs and toxins. 
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Anti-Stx1 (3E2) reacted with 0.1 μg of Stx1 up to 19.5 ng (Figure 2A), 2.5 μg of anti-Stx1 MAb was 
necessary to detect the same amount of Stx2 (Figure 2B). For anti-Stx2 (2E11) the reactivity with the 
Stx2 was up to 18.7 pg (Figure 2D) and 0.31 μg was necessary to detect Stx1 (Figure 2C). These 
results show that cross reactivity occurrs only in the presence of higher MAb concentrations, which are 
excessive to detected theirs respective toxins. 
The MAb stability parameters were quite different for both toxins. Anti-Stx2 MAb was stable up to 
70 °C, while anti-Stx1 lost stability at 50 °C (Table 1). Moreover, a higher temperature and more time 
were necessary for anti-Stx2 MAb to lose immunoreactivity compared with anti-Stx1 MAb (Table 1). 
Figure 2. Indirect ELISA using MAbs 3E2 and 2E11 and purified toxins Stx1 or Stx2. 
ELISA microtiter was coated with 0.1 μg of Stx1 (A and B) and Stx2 (C and D). The 
reaction was carried out using different concentrations of anti-Stx1 MAb, 3E2 (A and C) or 
anti-Stx2 MAb 2E11 (B and D). The cut-off was defined as 0.1 OD. Cross reactivity 
occurred at high MAbs concentration.  
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Table 1. Features of anti-Stx1 and anti-Stx2 MAbs. 
MAb characteristic Anti-Stx1 Anti-Stx2 
Hybridomas 3E2 2E11 
Dissociation constant (KD) 2.5 × 10−10 M 6.1 × 10−10 M 
Detection limit (200 ng)  6.2 ng 12.5 ng 
Thermostability  50º C 70º C 
Total loss of immunoreactivity (80 ºC) 1 min 5 min 
Partial loss of immunoreactivity 60 ºC and 70 ºC 80 ºC and 90 ºC. 
The kinetics of the toxins was analyzed by incubating the toxins at 0, 2, 6 and 24 h with Vero cells. 
After fixation, these interactions were visualized after the MAb reaction (Figure 3). In the early 
periods (0 and 2 h) each MAb recognized only their respective toxins, but after 6 h both MAbs were 
able to identify the presence of both toxins in Vero cells, shown by immunofluorescence. Using 
confocal microscopy, we observed that fluorescence emission with the homologous toxin was more 
intense. Presence of either Stx1 or Stx2 was observed along the cell when anti-Stx1 was employed 
(Figure 3). The pattern of recognition by the anti-Stx2 MAbs with either Stx1 or Stx2 was limited to 
the cell border (Figure 3). Assay specificity was assured by interaction of monoclonal antibodies with 
Vero cells in the absence of toxin (Figure 3). 
Figure 3. Immunofluorescence assay after Stx1 or Stx2 interaction with Vero cells for 0, 2, 
6 and 24 h. The reaction was carried out by incubating the cells with anti-Stx1 or anti-Stx2 
MAbs. Cells labeled with FITC displayed an apple green fluorescence, showing that MAbs 
were able to recognize the toxins after cell interaction. Reactivity of anti-Stx1 or anti-Stx2 
MAbs with cells and the anti-IgG mouse FITC in the absence of toxins was used as the 
negative control (C-), besides the differential interference contrast (DIC) of negative 
control. Reactivity was visualized with a confocal laser-scanning microscope  
(LSM 510 META). 
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Figure 3. Cont. 
 
MAb reactivity with STEC isolates was determined by capture ELISA. Data from this experiment 
showed not only MAb reactivity but also allowed us to infer which toxins were produced by STEC 
isolates, thus anti-Stx1 and anti-Stx2 MAbs detected the toxins expressed even at low levels (Table 2), 
demonstrating the diagnostic sensitivity of the MAbs. Furthermore, the reactivity of the MAbs 
matched the presence of the stx1 and stx2 genes, confirming their specificity. Just in one case  
(isolate O36, O75:H8), stx2 gene was amplified but the respective protein was not detected by  
anti-Stx2 MAb. However, stx1 gene was detected in the same isolate, and anti-Stx1 MAb recognized 
the respective toxin. 
Table 2. Shiga toxin (Stx)-producing Escherichia coli characteristics. 
Strain number Serotype Gene presence Reactivity to MAbs Anti-Stx1      Anti-Stx2 
597 OR:NM stx1 H - 
1132 ONT:H49 stx2 - H 
1189 ONT:H49 stx2 - H 
3003 O48:H7 stx1/stx2 M M 
4123 O26:H11 stx1 M - 
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Table 2. Cont. 
D360/4/1 O26:H11 stx1 M - 
1557-77 O26:H11 stx1 H - 
H30 O26:H11 stx1 M - 
H19 O26:H11 stx1 M - 
EPEC199 O26:H11 stx1 M - 
3529 O26:H11 stx1 M - 
82 O157:H7 stx1 H - 
46240 O157:H7 stx1/stx2 M H 
3104-88 O157:H7 stx1/stx2 M H 
3077-88 O157:H7 stx1 M - 
C7-88 O157:H7 stx1 L - 
C1520-77 O157:H7 stx1/stx2 H H 
1 O157:H7 stx2 - H 
2 O157:H7 stx2 - H 
4 O93:H19 stx1/stx2 H L 
5 O55:H19 stx1 L - 
9 O103:H2 stx1/stx2 H H 
11 O118:H16 stx1 M - 
16 O26:H11 stx1 L - 
20 O111:H8 stx1 L - 
23 O111:H8 stx1 L - 
26 O111:NM stx1 M - 
27 O111:NM stx1 M - 
41 ONT:NM stx2 - M 
44 O98:H4 stx1/stx2 M H 
45 O181:H4 stx1/stx2 M H 
53 O98:H17 stx1/stx2 L H 
55 O98:H17 stx1/stx2 M H 
59 ONT:H16 stx2 - L 
66 O105:H18 stx1/stx2 H H 
79 O22:H16 stx2 - H 
81 ONT:H38 stx1/stx2 H H 
82 O112:H21 stx2 - H 
96 O93:H19 stx2 - M 
O1 ONT:H8 stx1 L - 
O17 O112:H2 stx1 L - 
O3 O172:NM stx2 - H 
O22 ONT:H16 stx2 -                   L 
O36 O75:H8 stx1/stx2 M                    - 
O55 O146:H21 stx1/stx2 H                  L 
EDL 933 O157:H7 stx1/stx2 H                  H 
- —MAb reactivity lower than 0.99 ng; L—low level of MAb reactivity (1–30 ng); M—medium level of 
MAb reactivity (31–60 ng); H—high level of MAb reactivity (61–100 ng). Arbitrary classification based on 
the obtained absorbance with 100 ng purified Stx1 or Stx2, which was considered to be a high level of 
reactivity by capture ELISA. 
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3.2. Neutralizing Ability of Monoclonal Antibodies 
The CD50 of each toxin was determined prior to neutralization assays using anti-Stx1 and anti-Stx2 
MAbs. CD50 was defined as 10 ng and 500 ng for Stx1 and Stx2, respectively. Concentrations of  
anti-Stx1 MAb ranging from 1.28 ng to 100 µg neutralized between 30 and 80% of Stx1 cytotoxic 
activity (Figure 4A). Anti-Stx1 MAb showed cross-reactivity (Figure 4B), i.e., it inhibited both Stx1 
and Stx2 activity to the same extent. On the other hand, 100 µg or 200 µg anti-Stx2 MAb were 
necessary to neutralize ca. 35% of Stx2 activity, and 60% of neutralization was only achieved using 
500 µg MAb (Figure 4C). No apparent cell damage was observed in any MAb concentration.  
Figure 4. A and B—anti-Stx1 MAb showed cross-reactivity and was able to inhibit 
between 70 and 80% of both toxins ((A) Stx1 and (B) Stx2). Higher concentrations of  
anti-Stx2 MAb (100 to 500 µg) were necessary to neutralize Stx2 activity (C), but not Stx1 
(data not shown). Bars represent the mean and the standard errors of the percentage of 
duplicates of three independent experiments. 
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After determining the neutralization point for both MAbs, their ability to neutralize the cytotoxic 
activity of the STEC strains, belonging to several serotypes and showing either stx1, stx2 or stx1/stx2 
genes, was investigated. We observed that Stx activity was neutralized (from 25 to 80%) by the MAbs 
in all isolates (Figure 5). Besides, using both MAbs, we were able to neutralize Stx1 and Stx2 
expressed by isolates. Cellular integrity was maintained at these MAb concentrations in the absence of 
toxins. Means and variances were significantly different (p < 0.0001) by Student’s t-test and 2-way 
ANOVA, comparing the cytotoxicity and neutralization groups (Figure 5). 
Figure 5. Vero cell cytotoxicity assay (VCA) and neutralization assays with culture 
supernatant of 46 shiga toxin-producing Escherichia coli (STEC) isolates producing Stx1 
and/or Stx2 incubated with (blue) or without (red) anti-Stx1 and anti-Stx2 MAbs followed 
by cell incubation. Cytotoxicity and neutralization were determined after staining the cells 
with crystal violet and measuring absorbance at 595 nm. Means and variances were 
significantly different (p < 0.0001) by Student’s t-test and 2-way ANOVA comparing 
cytotoxicity and neutralization groups. Bars represent the OD means and standard errors 
median of duplicates of three independent experiments. A high OD value means high cell 
viability.  
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4. Discussion 
A number of anti-Stx MAbs showing different features have been described in the  
literature [19,23,24,30,35,44–49], including their use for diagnosis, but just for Stx1 and for O157:H7 
recognition [49]. Thus, raising monoclonal antibodies takes a remarkable effort, and developing them 
as tools for diagnosis or therapy is a major struggle.  
Anti-Stx1 and anti-Stx2 MAbs obtained in the present study were produced against toxins 
converted to toxoids by either formaldehyde or glutaraldehyde treatment [35,36]. The 3E2 clone was 
obtained in the first fusion after Stx1 treatment by glutaraldehyde and using the immunization and 
fusion protocols already described by our group either for the MAbs IgG2b anti-LT or IgG2b  
anti-intimin [50–52]. In contrast, the 2E11 clone was merely obtained after ten fusions, through 
different tested protocols either for toxoid conversion or route and schedule immunization. Among the 
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six clones obtained, only 2E11 produced antibodies that were reactive to Stx-producing strains with 
high affinity and showed no reactivity with non-Stx-expressing strains (data not shown). 
Anti-Stx1 and anti-Stx2 were classified as IgG1, as in case of MAbs already produced by other 
research groups as a consequence of the long schedule of mouse immunization with Stx  
toxoids [23,24,45]. Furthermore, these MAbs showed an efficient interaction with their respective 
toxin as indicated by their high dissociation constants and their ability to detect low levels of both 
purified toxins as well as low-producer isolates. In fact, among the described MAbs the affinity 
constant was cited in few studies. The studies by Tanikawa et al. [53] and Kimura et al. [26] showed 
the KD of 2.6 × 10−10 M for anti-Stx1 MAb and the KD of 2.3 × 10−9 M for anti-Stx2A MAb, which are 
similar to our described MAbs. 
Another important characteristic was the stability of MAbs at high temperatures and the reactivity 
of anti-Stx1 or anti-Stx2 with their homologous toxin by indirect ELISA. 3E2 reacted with the B 
subunit of Stx1, while 2E11 recognized the A subunit of Stx2 by immunoblotting. This variation in 
reactivity is very common and has been shown by other groups with anti-Stx1 MAbs that either react 
with the A subunit [28] or the B subunit [24] or are conformational [30]. MAbs against Stx2 reacting 
with either the A or B subunit have also been described [23,44,45,47]. In the present study, both MAbs 
recognized only their specific denatured toxin by immunoblotting. Besides, the cross reactivity was 
only observed using high antibody concentrations by indirect ELISA. Surprisingly, when native 
protein was used by in vitro interaction assay, both MAbs showed cross reactivity after 6 h of  
toxin-Vero cells interaction, despite different recognition patterns. 
An in vitro cytotoxicity assay was performed to evaluate the conditions by which the MAbs were 
able to neutralize the cytotoxic effects of Stx1 and/or Stx2. The neutralizing ability of the produced 
MAbs showed that anti-Stx1 MAb neutralized the binding of Stx1 and Stx2 to Vero cells. On the other 
hand, anti-Stx2 neutralized only the homologous toxin, and a higher concentration of this MAb was 
necessary. The correlation between subunit reactivity and neutralizing ability is variable. For example, 
Smith et al. [30] characterized a conformational MAb that neutralizes the Stx2 B subunit. The opposite 
was observed by Sheoran et al. [47] since the two MAbs tested failed to neutralize Stx2c in vitro due 
to their stronger reactivity with the B subunit than with the A subunit of Stx2 by immunoblotting. 
The clinical options for treatment of STEC still remain limited to mainly supportive strategies 
despite researchers’ efforts in understanding this pathogen. No MAb is currently approved for clinical 
use, but promising options for the future are under investigation, including urtoxazumab against Stx2, 
which is undergoing clinical trials and appears to be safe, making it a potential candidate for the 
prevention of HUS in pediatric patients [31]. Also, another human monoclonal antibody [27,28] 
protected mice against lethal challenges with Stx2 and Stx2 variants [47]. Preclinical evaluation in a 
piglet model of infection showed protection against Stx2-induced fatal neurological symptoms, even 
when the antibody was administered after the onset of diarrhea and oral STEC challenge [54]. 
Given that STEC can produce any combination of Stx1, Stx2, and/or variants [55], an ideal 
therapeutic formulation should include MAbs specific for all them, which could provide  
broad-spectrum protection against Stx1 and/or Stx2 [27,28,47]. Our results suggest that the 
manipulation by site-directed mutagenesis of the single chain fragment variable (ScFv) of MAbs 
should be interesting to improve their affinity and allow the large-scale production of recombinant 
antibodies with desirable sensitivity and specificity. This is currently under way in our laboratory. 
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Moreover, the previously described IgG-enriched fraction of anti-Stx1 or anti-Stx2 from rabbit 
polyclonal antiserum [33,34] together with anti-Stx1 or anti-Stx2 MAbs, showed high sensitivity in 
detecting Stx even in low-producer isolates by capture ELISA. Therefore, both MAbs can be used as 
tools for the diagnosis of STEC in view of their described features. Since antibody neutralizing 
efficiency in vivo usually correlates with its ability to protect cells against Stx-mediated toxicity [56], 
the in vitro neutralizing abilities of the described MAbs against the Shiga toxins encourage future 
studies to investigate their protective efficacy. 
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